TRD

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

Retrieved on: 
Giovedì, Maggio 11, 2023
Well, Consensus, Psilocybin, Acceleration, PK, Insurance, GABA, DMT, Society, MCCB, PD, IV, D&O, Benzodiazepine, OTF, VAT, Anorexia nervosa, COMP, PTSD, G&A, Part, Accounting, Anxiety disorder, Patient, Investment, Administration, EEG, Biological Psychiatry (journal), Annual general meeting, Pivotal, CIAS, Entrepreneurship, Oxygen toxicity, Research and development, Research, R, TRD, Safety, Cognitive deficit, Pharmaceutical industry, Palladium, Bank, Surveying, Schizophrenia

The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.

Key Points: 
  • The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.
  • NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates.
  • “This past quarter we made significant progress, including the dosing of the first patient with RL-007 in a randomized, placebo-controlled Phase 2 study.
  • In January 2023, Phase 1 results were announced from the study of GRX-917 in healthy volunteers.

Toyota Racing Development announces official relationship with Segra

Retrieved on: 
Mercoledì, Maggio 10, 2023
Sports, Technology, Mobile, Wireless, Telecommunications, Motor Sports, Internet, Circuit, Partnership, Toyota Racing Development, Apex Tool Group, Stratasys, Yahoo!, ExxonMobil, TRD, GF, Selective glucocorticoid receptor modulator, IP

Toyota Racing Development (TRD) is pleased to announce an official partnership with Segra, one of the largest independent fiber infrastructure bandwidth companies in the Eastern U.S. With over a century of helping customers achieve connectivity, Segra has been named as the Official IT Infrastructure Partner of TRD, along with receiving official status in Toyota’s single-make series, the GR Cup.

Key Points: 
  • Toyota Racing Development (TRD) is pleased to announce an official partnership with Segra, one of the largest independent fiber infrastructure bandwidth companies in the Eastern U.S. With over a century of helping customers achieve connectivity, Segra has been named as the Official IT Infrastructure Partner of TRD, along with receiving official status in Toyota’s single-make series, the GR Cup.
  • “We are honored to have been chosen as the Official IT Infrastructure Partner for Toyota Racing Development,” says Kevin T. Hart, CEO of Segra.
  • Segra joins a wide ranging list of official TRD partners, including ExxonMobil, HARMAN Automotive, Safelite AutoGlass, Apex Tool Group, Yahoo, Stratasys, GF Machining Solutions and Racing Force Group.
  • “We are pleased to announce this official relationship with Segra,” said David Wilson, president, TRD.

HMNC Brain Health Appoints Evan Papanastasiou as VP Clinical Development

Retrieved on: 
Lunedì, Maggio 8, 2023
Lundbeck, PhD-MBA, MBA, Research, DSM-IV codes, Doctor of Philosophy, CNS, Boehringer Ingelheim, MDD, Patient, MD, Treatment-resistant depression, American College, TRD, Mental health, Major depressive disorder, Pharmaceutical industry, Nursing, Psychosis

MUNICH, Germany, May 08, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today the appointment of Dr. Evan Papanastasiou, MD MSc PhD MBA, as VP Clinical Development, to lead pre-clinical and clinical programs and support new development opportunities at the Company.

Key Points: 
  • MUNICH, Germany, May 08, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today the appointment of Dr. Evan Papanastasiou, MD MSc PhD MBA, as VP Clinical Development, to lead pre-clinical and clinical programs and support new development opportunities at the Company.
  • In his new role, Dr. Papanastasiou will be responsible for the strategy, direction, and execution of the Company’s clinical development plans, such as progressing HMNC Brain Health’s Ketabon program towards the pathway of commercialization.
  • Most recently, Dr. Papanastasiou served as the Global Clinical Program Leader at Boehringer Ingelheim, where he was responsible for the ongoing refinement of clinical development pathways; coordination of scientific & cross-functional teams in a matrix environment.
  • “I am looking forward to joining the clinical leadership team at HMNC Brain Health as they are disruptors in the mental health industry and personalizing treatments that benefit individual patients rather than serving the one-size-fits-all current standard of mental health treatment.

First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression

Retrieved on: 
Giovedì, Maggio 4, 2023
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Depression, Pharmacokinetics, DSM-IV codes, Investigational New Drug, Patient, Atypical depression, FDA, TRD, IND, Treatment, Food, Safety, Pharmaceutical industry

Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into effective and licensed medicines, announced today that the first patient has been dosed in its Phase IIa study evaluating BPL-003 as a potential therapy for Treatment Resistant Depression (TRD).

Key Points: 
  • Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into effective and licensed medicines, announced today that the first patient has been dosed in its Phase IIa study evaluating BPL-003 as a potential therapy for Treatment Resistant Depression (TRD).
  • BPL-003 is Beckley Psytech’s novel synthetic formulation of the psychedelic compound 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device.
  • Phase I data has already shown BPL-003 to be well-tolerated with consistent dose delivery and a reproducible, dose-proportional pharmacokinetic profile.
  • Around one third of all people living with depression are resistant to currently available antidepressants and there is an urgent need for more effective treatments.

Toyota Partners with LEGACY MOTOR CLUB Beginning with the 2024 Cup Series Season

Retrieved on: 
Martedì, Maggio 2, 2023
GMS, NASCAR Cup Series, Bell, Partnership, NCTS, Phoenix Raceway, LAS, 2007 NASCAR Nextel Cup Series, NASCAR Craftsman Truck Series, Toyota Motor North America, GMS Racing, Darlington, Daytona, Season, TMNA, Toyota Motor Sales, USA, 2023 NASCAR Cup Series, Richmond Raceway, History, Kyle, Toyota Racing Development, NCS, NASCAR Xfinity Series, Noah Gragson, Texas Motor Speedway, The King, Johnson, Humble Duty, Rookie of the Year, TRD, Family, Character, NXS, Automotive industry, Toyota Camry, NASCAR

PLANO, Texas, May 2, 2023 /PRNewswire/ -- Toyota is pleased to announce a partnership with LEGACY MOTOR CLUB beginning with the 2024 NASCAR Cup Series (NCS) season.

Key Points: 
  • PLANO, Texas, May 2, 2023 /PRNewswire/ -- Toyota is pleased to announce a partnership with LEGACY MOTOR CLUB beginning with the 2024 NASCAR Cup Series (NCS) season.
  • "All of us at Toyota are thrilled to add LEGACY MOTOR CLUB to our NASCAR family," said Jack Hollis, executive vice president of TMNA (Toyota Motor North America) and president of Toyota Motor Sales.
  • "Maury Gallagher and I are very excited about the partnership with Toyota and TRD beginning in 2024," said LEGACY M.C.
  • "We are humbled and delighted to welcome LEGACY MOTOR CLUB into the Toyota and TRD NASCAR family," said David Wilson, president of TRD, U.S.A. (Toyota Racing Development).

American Medical Association to Issue First New Code for Psychedelic Therapies

Retrieved on: 
Martedì, Maggio 2, 2023
Intervention, The New England Journal of Medicine, CPT, PBC, COMPASS, American Medical Association, Documentation, MAPS, Post-traumatic stress disorder, Physician, SAN, AMA, CMPS, FDA, Panel Action Bingo, TRD, Mental health, III, PTSD, Pharmaceutical industry

The full details of the code are expected to be released by the AMA in July 2023 and the code will go into effect when it is published on January 1, 2024.

Key Points: 
  • The full details of the code are expected to be released by the AMA in July 2023 and the code will go into effect when it is published on January 1, 2024.
  • Once effective, the CPT code will provide physicians and other qualified healthcare professionals a means to code and seek reimbursement for delivering psychedelic therapies.
  • The application for the new CPT III code was the result of a collaboration between MAPS PBC and COMPASS Pathways to facilitate reimbursement and ultimately access to psychedelic therapies in the US, if approved by the US Food Drug Administration (FDA).
  • “This is a major step forward to enabling broad and equitable access to psychedelic therapies,” said Kabir Nath, CEO, COMPASS Pathways.

Breaking Through ‘Untreatable’ Depression and Anxiety with Ketamine

Retrieved on: 
Lunedì, Aprile 24, 2023
Mental Health, Health, Anxiety, Exercise, Ketamine, Depression, Rapid City Public Library, TRD, Medicine, Patient, SD, Pharmaceutical industry, Medical device

Specializing in treating the most interminable depression cases, Manlove Brain + Body Clinic has been using ketamine for four years to help patients with ‘untreatable’ depression or anxiety make significant breakthroughs.

Key Points: 
  • Specializing in treating the most interminable depression cases, Manlove Brain + Body Clinic has been using ketamine for four years to help patients with ‘untreatable’ depression or anxiety make significant breakthroughs.
  • 70% of treatment resistant depression (TRD) patients have seen a significant improvement in their depression symptoms with ketamine, compared to the 10% chance they would see if they tried yet another common antidepressant medication.
  • In some cases, patients even find that their depression is eliminated completely.
  • Psychiatrist Dr. Stephen Manlove is hosting a free educational session–Ketamine for Depression and Anxiety–at the Rapid City Public Library on Monday, May 1st from 5:30-6:30pm.

Psychiatrists Call for Ketamine Insurance Coverage

Retrieved on: 
Giovedì, Aprile 20, 2023
Mental Health, Public Policy, Government, Healthcare Reform, Health, Health Insurance, Pharmaceutical, Insurance, Depression, Anxiety, Multimedia, Medicine, Incidence, Ketamine, Patient, FDA, TRD, Mental health, PTSD, Nursing, Pharmaceutical industry, Hospital

Leading psychiatrists are challenging inconsistent medical insurance coverage for ketamine, a key medication for patients with treatment-resistant depression, anxiety and other severe mental health conditions.

Key Points: 
  • Leading psychiatrists are challenging inconsistent medical insurance coverage for ketamine, a key medication for patients with treatment-resistant depression, anxiety and other severe mental health conditions.
  • And in too many cases, insurance coverage is the only barrier.”
    The blog details seven reasons why ketamine should be insured and encouraged for severely depressed and suicidal patients:
    Ketamine is in general use in the medical community in the US and internationally.
  • Ketamine has been proven safe and effective—in fact it can be life-saving—for depression and anxiety patients who have often found no relief from traditional antidepressants.
  • Oklahoma City psychiatrist Rachel Dalthorp is actively appealing to Oklahoma legislators and medical directors at major insurers to move ketamine insurance forward.

Red Cell Partners Announces $3 Million in Pre-Seed Funding for Psychedelic Company TARA Mind

Retrieved on: 
Giovedì, Aprile 13, 2023
Pharmaceutical, Health, Neurology, Mental Health, Red Cell, Partnership, Depression, Icahn School of Medicine at Mount Sinai, Suicide, Integration, Absenteeism, Professional corporation, Health equity, Veteran, Human, Multimedia, Harvard Medical School, Mount Sinai, Doctor of Philosophy, Science, Stanford University School of Medicine, MDD, MD, Post-traumatic stress disorder, Standard of care, Mental, Navy, Traumatic brain injury, Behavioural sciences, PAT, Entrepreneurship, ROI, TRD, Death, Mental health, Society, Fourth Estate Public Benefit Corporation, Safety, Major depressive disorder, Pharmaceutical industry, Nursing, Psychotherapy, Medicine, Trauma, Practitioner, Psychiatry

Red Cell Partners, an incubation firm building and investing in technology-led companies that bring revolutionary advancements to healthcare and national security, has announced $3 million in pre-seed funding for TARA Mind, a mental health company that enables safe and affordable access to psychedelic-assisted therapy (PAT).

Key Points: 
  • Red Cell Partners, an incubation firm building and investing in technology-led companies that bring revolutionary advancements to healthcare and national security, has announced $3 million in pre-seed funding for TARA Mind, a mental health company that enables safe and affordable access to psychedelic-assisted therapy (PAT).
  • The problem is a large and complicated one exacerbated by misaligned incentives, a global pandemic, and deep-rooted stigma surrounding psychedelics and other alternative therapies.
  • “Far too many people are being failed by our country’s outdated approach to mental health care,” said Red Cell CEO and TARA Mind Co-Founder, Grant Verstandig.
  • At TARA Mind, we aren’t being guided by ‘the buzz’ around psychedelics, nor are we chasing a quick profit from lingering loopholes in a post-COVID world.

Beckley Psytech initiates Phase IIa study of 5-MeO-DMT candidate BPL-003 for Alcohol Use Disorder

Retrieved on: 
Mercoledì, Aprile 5, 2023
Biotechnology, Technology, Health, Pharmaceutical, Mental Health, Health Technology, Other Technology, Medical Devices, Research, Science, Clinical Trials, Drug development, Phases of clinical research, Beckley Foundation, Pharmacokinetics, King's College London, DSM-IV codes, University College London Hospitals NHS Foundation Trust, Death, AUD, MDD, Patient, Atypical depression, King, FDA, TRD, Treatment, Safety, Major depressive disorder, Pharmaceutical industry

Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into effective and licensed medicines, today announced that it has initiated a Phase IIa study ( NCT05674929 ) investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD).

Key Points: 
  • Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into effective and licensed medicines, today announced that it has initiated a Phase IIa study ( NCT05674929 ) investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD).
  • Beckley Psytech’s Phase IIa study, taking place at King’s College Hospital in London, will explore the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD).
  • Alcohol use disorders are estimated to affect around 237 million people across the globe , with 3 million deaths each year attributed to the harmful use of alcohol.
  • Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “There is increasing evidence demonstrating the therapeutic effect of psychedelics for substance use disorders.